The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

Sanofi (SNY) Reports Board Resignation of Christian Mulliez and Co-Opts Christophe Babule to Board PositionFebruary 6, 2019 4:54 PM Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)February 6, 2019 11:45 AM